Targeting the SNS is an emerging area in cancer treatment. Beta-blockers, which inhibit the effects of norepinephrine, have shown promise in reducing tumor growth and metastasis in preclinical studies. Clinical trials are ongoing to evaluate their efficacy in cancer patients.
